SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PaxMedica, Inc. Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

01/07/2022 | 08:00am EDT

PaxMedica, Inc. announced that it has received approval from the South African Health Products Regulatory Agency (SAHPRA) for its clinical trial application to study the effects of PAX-101 (suramin intravenous (IV) infusions) in patients with Long COVID-19 Syndrome (LCS), also known as post-acute sequelae of SARS-CoV-2 infection. The study, PAX-LCS-101, will be a Phase 1B, prospective, randomized, placebo-controlled, double-blind, multiple-dose study. The study is expected to start enrolling patients in the first quarter of this year after obtaining South African National Ethics Committee approval. LCS is a serious, multi-system illness that results in significant impairment of functioning in many individuals after acute infection with COVID-19. The diagnosis of LCS is challenging as there are no specific tests to establish the diagnosis. Although there are many definitions proposed in the medical literature, most researchers define LCS as a syndrome that includes a protracted course of various physical and neuropsychiatric symptoms that persist for 12 weeks or more without an alternative explanation. The study is expected to enroll patients with persistent signs and symptoms of LCS, after a previously documented infection with the COVID-19 virus. The symptoms of LCS in each patient can vary but often include fatigue, "brain fog", pain, headaches, shortness of breath, difficulty with concentration and attention, sleep disturbance, orthostasis and dizziness, and decreased functioning as well as many associated symptoms such as joint and muscle pain, depression and anxiety. LCS has been observed to closely resemble another post-acute infection disorder known as myalgic encephalomyelitis /chronic fatigue syndrome (ME/CFS). In both disorders, fatigue is a prominent symptom and many of the other observed symptoms overlap. Both conditions may result in an inability to work or perform normal activities and in extreme cases of ME/CFS, have been documented to last for years, resulting in those affected becoming home-, if not bed-bound. PaxMedica plans to study PAX-101 as a treatment for both LCS and ME/CFS. This clinical trial is planned to study the safety and tolerability, efficacy, and PK of two doses of suramin (5 mg/kg and 10 mg/kg) in adults, 18 years and older, with LCS. Despite the significant unmet medical need for treatments of LCS, there are no currently approved medications for this disorder. There is growing consensus in the scientific and medical communities of the need for more research into the causes of LCS, and the potentially related disorder ME/CFS PAX-101 is also currently in Phase 2 for Autism Spectrum Disorder ("ASD"). The Company is also developing PAX-102, a proprietary intranasal formulation of suramin, for ASD and other neurologic disorders.

© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
EVOLUTION AB -5.03% 929 Delayed Quote.-23.95%
PAXMEDICA, INC. 0.00%End-of-day quote.0.00%
All news about PAXMEDICA, INC.
04/25PaxMedica, Inc. announced a financing transaction
01/07PaxMedica, Inc. Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVI..
01/04PaxMedica, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021
2021Paxmedica, Inc. Presents Clinical Data and New Analyses from A Phase 2 Trial of Pax-101..
2021PaxMedica to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Chil..
2021PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Chil..
2020PaxMedica, Inc. announced that it has received $3 million in funding
2020PaxMedica, Inc. announced that it expects to receive $3 million in funding
2020PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million.
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -7,83 M - -
Net cash 2020 0,51 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 59,1 M 59,1 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 5
Free-Float 26,3%
Income Statement Evolution
Managers and Directors
Joseph Lucchese Chief Financial Officer
Zachary Rome Chief Operating Officer & Director
Karen T. Dawes Independent Director
Paul Kevin Wotton Independent Director
Robert F. Apple Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569